KRAS and lung carcinoma: Through in vivo shRNA-mediated high-throughput screening, EphA2 was identified as a tumor suppressor in KRasG12D-induced human lung cancers with a wild-type TP53 genetic background [13], which carries a mutated K-ras that causes constitutive Akt and ERK activation.